The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment

被引：0
|
作者：
Jin, Feng [1 ]
Robeson, Michelle [2 ]
Zhou, Huafeng [2 ]
Hisoire, Grace [1 ]
Ramanathan, Srini [1 ]
机构：
[1] Gilead Sci Inc, Foster City, CA 94404 USA
[2] Gilead Sci Inc, Seattle, WA USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT204
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Safety and pharmacokinetics of SPR206 in subjects with varying degrees of renal impairment
    Bruss, Jon B.
    Bader, Justin
    Hamed, Kamal A.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (11)
  • [42] Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment
    Garimella, Tushar
    Wang, Reena
    Luo, Wen-Lin
    Hwang, Carey
    Sherman, Diane
    Kandoussi, Hamza
    Marbury, Thomas C.
    Alcorn, Harry
    Bertz, Richard
    Bifano, Marc
    ANTIVIRAL THERAPY, 2015, 20 (05) : 535 - 543
  • [43] Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
    Yukio Shimasaki
    Masashi Sakaki
    Minoru Itou
    Tokurou Kobayashi
    Masako Aso
    Tomoya Kagawa
    Takuya Saiki
    Kumi Matsuno
    Yuhei Sano
    Kohei Shimizu
    Shingo Kuroda
    Emiko Koumura
    Clinical Drug Investigation, 2018, 38 : 1041 - 1051
  • [44] Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
    Shimasaki, Yukio
    Sakaki, Masashi
    Itou, Minoru
    Kobayashi, Tokurou
    Aso, Masako
    Kagawa, Tomoya
    Saiki, Takuya
    Matsuno, Kumi
    Sano, Yuhei
    Shimizu, Kohei
    Kuroda, Shingo
    Koumura, Emiko
    CLINICAL DRUG INVESTIGATION, 2018, 38 (11) : 1041 - 1051
  • [45] Lucerastat, an iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment
    Guerard, Nicolas
    Zwingelstein, Christian
    Dingemanse, Jasper
    MOLECULAR GENETICS AND METABOLISM, 2017, 120 (1-2) : S59 - S59
  • [46] Lucerastat, an Iminosugar for Substrate Reduction Therapy: Pharmacokinetics, Tolerability, and Safety in Subjects With Mild, Moderate, and Severe Renal Function Impairment
    Guerard, Nicolas
    Zwingelstein, Christian
    Dingemanse, Jasper
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (11): : 1425 - 1431
  • [47] Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment
    Jamieson, Brian D.
    Ciric, Sabrina
    Fernandes, Prabhavathi
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) : 4379 - 4386
  • [48] Pharmacokinetics and Safety of Teneligliptin in Subjects With Hepatic Impairment
    Halabi, Atef
    Maatouk, Haidar
    Siegler, Karl Ernst
    Faisst, Nadja
    Hinrichsen, Holger
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2014, 3 (04): : 290 - 296
  • [49] PHARMACOKINETICS AND SAFETY OF NITAZOXANIDE IN SUBJECTS WITH HEPATIC IMPAIRMENT
    Harisseh, Rania
    Finnegan, Beth
    Thomas, Stephane
    Legry, Vanessa
    Hum, Dean
    Marbury, Thomas C.
    Perry, Robert G.
    Wyatt, David J.
    Addy, Carol
    GASTROENTEROLOGY, 2023, 164 (06) : S1391 - S1391
  • [50] Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment
    Angelika Weil
    Paul Martin
    Robert Smith
    Stuart Oliver
    Peter Langmuir
    Jessica Read
    Karl-Heinz Molz
    Clinical Pharmacokinetics, 2010, 49 : 607 - 618
12345